Evidence map›Paper›PMID 42070274›Full record

ArticleThe Prostate2026

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis.

Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer-Mileo, Laia Fernández-Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marta Garcia de HerrerosMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Clara RodrigoMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Laura Ferrer-MileoMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Laia Fernández-MañasMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Joel MasesRadiation Oncology Department, Hospital Clinic, Barcelona, Spain.
Nely DiazMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Antoni VilasecaUrology Department, Hospital Clinic, Barcelona, Spain.
Mariana AltamiranoMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Roser GibanelUrology Department, Hospital Clinic, Barcelona, Spain.
Maria José RibalUrology Department, Hospital Clinic, Barcelona, Spain.
Natalia JimenezTranslational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
Oscar ReigMedical Oncology Department, Hospital Clinic, Barcelona, Spain.
Mariona FigolsMedical Oncology Department, Fundació Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain.
Miguel Ángel ClimentMedical Oncology Service, Instituto Valenciano de Oncología (IVO), Valencia, Spain.
Albert FontMedical Oncology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.
Begoña MelladoMedical Oncology Department, Hospital Clinic, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs overall survival improves in metastatic hormone-sensitive prostate cancer (mHSPC), non-cancer causes of death are increasingly relevant.

methodsWe conducted a real-world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration-resistant prostate cancer (CRPC) were classified as cancer- or non-cancer-related. Deaths were classified as non-cancer-related if they occurred in the absence of cancer progression.

resultsAmong 565 patients, 35 (6.2%) died from non-cancer-related causes without disease progression, mainly infections (34%) and cardiovascular events (20%).

conclusionsNon-cancer mortality represents a meaningful proportion of deaths in mHSPC, supporting systematic cardiovascular risk evaluation and infection-prevention strategies.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAndrogen AntagonistsCardiovascular DiseasesCause of DeathDisease ProgressionHumansMaleMiddle AgedNeoplasm MetastasisAndrogen Antagonistscardiovascular riskcomorbiditiesnon‐cancer mortalityprostate cancer

Identifiers

PMID42070274
PMCPMC13270077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.